Injection Pen Market (By Product Type: Reusable and Disposable; By Therapy: Diabetes, Cancer, Osteoporosis, Autoimmune Diseases, Growth Hormone Therapy, Multiple Sclerosis, Fertility, Cardiovascular Diseases, Others; By End User: Hospitals & Diagnostic Centers and Homecare) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 – 2030


The global injection pen market was valued at US$ 37.72 billion in 2021 and is expected to reach over US$ 79.3 billion by 2030 and poised to grow at a CAGR of 6.7% from 2021 to 2030.

Injection Pen Market Size 2020 to 2030

Growth Factors

There are several factors such as growing prevalence of chronic diseases, technological advancements in the drug delivery devices, rising investments in research and clinical trials, rising number of government approvals, and favorable reimbursement policies are significantly driving the growth of the global injection pen market. The inconveniences associated with the traditional syringes is the prominent factors that are shifting the consumer preference towards the advanced injection pens. The growing investments by the pharmaceutical manufacturers in the development of new drugs is fueling its demand among the consumers, which in turn is boosting the demand for the injection pens for efficiently administering drugs. The growing healthcare expenditure and rising awareness regarding the availability of the innovative injection pens is spurring the growth of the global injection pen market. The conveniences associated with the injection pens allows the patients to self-administer drugs without the need for any professional assistance, which also reduces the cost. Hence, the injection pens are gaining rapid traction among the patients who frequently requires to administer drugs.

The rising burden of chronic diseases such as cancer, diabetes, autoimmune diseases, and cardiovascular diseases is exponentially contributing towards the growth of the injection pen market. According to the International Agency for Research on Cancer, in 2020, around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe. According to the International Diabetes Federation, currently around 537 million people are living with diabetes and this number is expected to reach at 783 million by 2045. According to the World Health Organization, diabetes is a major cause of kidney failure, blindness, and stroke. Moreover, cardiovascular diseases accounts for 32% of the global deaths and it is the leading cause of death across the globe. Therefore, the growing prevalence of various chronic and non-communicable diseases among the global population is expected to spur the demand for the injection pen market across the globe.

Scope of the Injection Pen Market

Report Coverage Details
Market Size in 2021 USD 37.72 Billion
Growth Rate from 2021 to 2030 6.7%
Largest Market North America
Fastest Growing Market Asia Pacific
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Product, Therapy, End User, Region
Companies Mentioned Eli Lilly, Novo Nordisk, Sanofi, Merck, AstraZeneca, Ypsomed, F.Hoffman-La Roche, Becton Dickinson and Company, Novartis, Pfizer, Haselmeier, Owen Mumford, WOCKHARDT, Companion Medical

 

Product Type Insights

The disposable segment dominated the global injection pen market in 2020. This is attributed to the safety and affordability associated with the disposable injection pens. The disposable injection pens can be used only once and it promotes the safety against the blood-borne diseases that occurs through the reusability of the injections. The easy availability, increased consumer awareness, rising healthcare expenditure, and rising prevalence of insulin related diseases has fostered the growth of the disposable injection pen segment in the past few years.

The reusable is estimated to be the most opportunistic segment during the forecast period. This can be attributed to the long life cycle of the reusable pens. The frequent users of the injection pens acquires the reusable injection pens once and it lasts for several years. This facilitates convenience to the patients. This growing awareness regarding the benefits of the reusable injection pens among the patients is expected to foster the growth of this segment in the forthcoming years.

Therapy Insights

Based on the therapy, the global injection pen market was dominated by the diabetes segment. The unhealthy food habits results in the increasing blood glucose levels. It is a major cause of type 1 diabetes. When the body becomes resistant to insulin, it results in the occurrence of type 2 diabetes. The rising prevalence of type 1 and type 2 diabetes among the global population is fueling the growth of this segment. According to the International diabetes federation, the global diabetic population is estimated to reach at 643 million by 2030.

The cancer is estimated to be the fastest-growing segment. This rising cases of cancer owing to rising prevalence of smoking, growing alcohol and tobacco consumption, rising consumption of processed food, and various other factors, the number of cancer cases is expected to grow rapidly. According to the International Agency for Research on Cancer, the global cancer cases are estimated to grow by 47% from 2020 to 2040. It is expected that 28.4 million cases will be recorded in 2040, globally. The lungs cancer, breast cancer, and prostate cancer are the most prominent cancer types across the globe.

End User Insights

Based on the end user, the homecare segment dominated the global injection pen market in 2020. The increased awareness regarding the injection pens, rising disposable income, rising consumer expenditure on healthcare, and growing adoption of innovative drug delivery devices among the patients to manage diseases are the major factors that boosts the growth of this segment. The injection pens allow the patients to self-inject drugs by eliminating the healthcare professional assistance and hence, the homecare segment has witnessed a significant growth in the global injection pen market.

Regional Insights

Based on region, North America dominated the global injection pen market in 2020. This is attributed to the increased prevalence of non-communicable diseases such as diabetes, cancer, cardiovascular diseases, and multiple sclerosis in the developed market like US and Canada. According to the US CDC, around 34.2 million people were living with diabetes and around 88 million people had pre-diabetes in US in 2020. The increased prevalence of diabetes among the US population has boosted the adoption of injection pen. The increased health consciousness, higher healthcare expenditure, increased awareness regarding the innovative drug delivery devices, and easy availability of injection pens and its cartridges are the major factors that has augmented the growth of the North America injection pen market.

Asia Pacific is estimated to be the most opportunistic market during the forecast period. The growing prevalence of various chronic diseases among the population owing to the unhealthy food habits, physical inactivity, and increasing consumption of alcohol and tobacco among the youth population. Most of the deaths due to the chronic diseases are recorded in the low and middle income countries, which offers the huge growth potential to the market players in Asia Pacific region.

Key Market Developments

  • In April 2020, Sanofi acquired the US FDA approval for its new prefilled pen named Dupixent that serves the asthma, chronic rhinosinusitis, and atopic dermatitis patients at homecare.
  • In June 2019, Sanofi acquired the EMA approval for its ToujeoSoloStar Pens in Europe.
  • In October 2017, Eli Lilly launched Humalog Junior KwikPen for the U.S. diabetic patients.

The various developmental strategies like product launches, acquisitions and mergers fosters market growth and offers lucrative growth opportunities to the market players.

Some of the prominent players in the global injection pen market include:

  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Merck
  • AstraZeneca
  • Ypsomed
  • F.Hoffman-La Roche
  • Becton Dickinson and Company
  • Novartis
  • Pfizer
  • Haselmeier
  • Owen Mumford
  • WOCKHARDT
  • Companion Medical

Segments Covered in the Report

By Product Type

  • Reusable
  • Disposable

By Therapy

  • Diabetes
  • Cancer
  • Osteoporosis
  • Autoimmune Diseases
  • Growth Hormone Therapy
  • Multiple Sclerosis
  • Fertility
  • Cardiovascular Diseases
  • Others

By End User

  • Hospitals & Diagnostic Centers
  • Homecare

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of Middle East & Africa

Frequently Asked Questions

What is the current size of injection pen market?
According to Precedence Research, the global injection pen market size was reached at US$ 37.72 billion in 2021 and is projected to surpass US$ 79.3 billion by 2030.
The global injection pen market is expected to drive growth at a CAGR of 6.7% from 2021 to 2030.
Some of the prominent players in the global injection pen market such as Eli Lilly, Novo Nordisk, Sanofi, Merck, AstraZeneca, Ypsomed, F.Hoffman-La Roche, Becton Dickinson and Company, Novartis, Pfizer, Haselmeier, Owen Mumford, WOCKHARDT, Companion Medical.
The global injection pen market is significantly driven by several factors such as rising prevalence of various chronic diseases, technological advancements in the drug delivery devices, development of innovative drugs, and rising awareness regarding the availability of innovative drugs and drug delivery devices among the population.
North America dominated the global injection pen market. The increased prevalence of non-communicable diseases among the US population is a significant driver of the market.
Asia Pacific is estimated to be the most opportunistic market during the forecast period. This can be attributed to the rising burden of chronic diseases among the population.

PROCEED TO BUY

   USD 4500
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample